ID
45956
Descripción
Principal Investigator: Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA MeSH: Carcinoma,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000855 The purpose of the study was to compare gene expression profiles from a cohort of crizotinib-resistant ALK-rearranged lung tumors and a cohort of treatment-naive ALK-rearranged lung tumors. Expression profiles were generated by RNA-seq. In parallel, gene expression profiles were obtained from ALK-rearranged lung cancer cell lines in the presence or absence of the ALK inhibitor TAE684. Gene expression profiles were also obtained from ALK-rearranged cells ectopically expressing genes associated with ALK inhibitor resistance that were identified from a functional genetic study.
Link
Palabras clave
Versiones (2)
- 15/3/24 15/3/24 - Dr. Christian Niklas
- 16/3/24 16/3/24 - Madita Rudolph
Titular de derechos de autor
Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
Subido en
16 de marzo de 2024
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000855 Resistance studies in Lung Cancer
Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID and sext of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
Similar models
Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID and sext of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
C0441833 (UMLS CUI [1,2])
Sin comentarios